A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

por Zelek, L, Yovine, A, Brain, E, Turpin, F, Taamma, A, Riofrio, M, Spielmann, M, Jimeno, J, Misset, J L
Publicado 2006